Kabra Drugs Ltd. (KABRADG) — Tipsheet

Kabra Drugs lands ₹200 cr LOI from Chhattisgarh for pharma plant

Tipsheet Editorial — Sat, 13 Jun 2026 15:57:38 GMT

The nano-cap pharma firm received a letter of intent from the state government for a facility at Nava Raipur Pharma Park, an investment worth over 3.5 times its market cap.

What’s new

Received LOI from Chhattisgarh for ₹200 cr pharma plant at Nava Raipur Pharma Park.
Project expected to create approximately 250 direct and indirect jobs.
Non-binding, subject to definitive agreements and approvals.

Why it matters

For a nano-cap with just ₹55 cr market cap, a ₹200 cr investment is an over 3.5 times bet on scale. It could push revenue far beyond the ₹92.74 cr achieved in FY26. State backing adds credibility, but the LOI is non-binding. Execution, including financing and approvals, remains the open question.

What we’re watching

Execution of definitive agreements and receipt of state incentives.
How the company plans to finance a capex over 3.5 times its market cap.
Timeline for construction and revenue contribution from the new facility.

The full read

Kabra Drugs went from zero revenue to ₹92.74 crore in a single year. Now it wants to do something far bigger. The company received a Letter of Intent from the Chhattisgarh government for a ₹200 crore pharmaceutical plant at Nava Raipur Pharma Park, an investment over 3.5 times its current market cap of ₹55 crore. The project would add around 250 jobs and expand manufacturing capacity drastically. But the LOI is non-binding. The real test is whether a nano-cap with ₹0.02 debt-to-equity and a P/E of 11.1 can secure financing and clear state approvals. If it does, Kabra could quintuple its scale. If not, the stock has already priced in a moonshot.

Primary source: BSE · NSE

Kabra Drugs goes from zero revenue to ₹92.74 cr in one year

Tipsheet Editorial — Fri, 29 May 2026 22:21:30 GMT

The nano-cap swung to a ₹4.96 cr profit after a ₹1.08 cr loss last year. A new manufacturing strategy delivered ₹35 cr in the final quarter alone.

What’s new

Kabra Drugs reported FY26 revenue of ₹92.74 cr, having recorded no revenue the prior year.
Net profit came in at ₹4.96 cr, reversing a FY25 net loss of ₹1.08 cr.
Q4 contributed over ₹35 cr, signaling the ramp is accelerating.

Why it matters

For a company with a ₹59 cr market cap, a ₹92.74 cr topline from a standing start is not incremental growth—it's a business reset. The move into multi-sector manufacturing has produced tangible results, and auditors signed off without qualification. The numbers are real.

What we’re watching

Whether the ₹92.74 cr run-rate holds or if FY25 was a one-off contract cycle.
Margin profile once the new manufacturing operations mature.
Whether the concessional tax regime provides a meaningful profit tailwind in FY27.

The full read

Kabra Drugs went from zero revenue in FY25 to ₹92.74 crore in FY26. That is not a recovery. It is the start of a different company. The ₹4.96 crore net profit reverses a ₹1.08 crore loss, and auditors signed off without qualification. For a firm with a ₹59 crore market cap, the scale of the shift is hard to overstate. Over ₹35 crore of that revenue arrived in the final quarter, so the business is still ramping. The company says it has moved into new manufacturing sectors and shifted to a concessional tax regime. Both moves are now in the numbers. The open question is whether the contracts that drove the ₹92.74 crore topline are recurring or project-based.

Primary source: BSE · NSE

Kabra Drugs' revenue jumped from zero to ₹92.74 cr in a single year

Tipsheet Editorial — Fri, 29 May 2026 20:35:59 GMT

The nano-cap's new manufacturing strategy swung it from a ₹1.08 cr loss to a ₹4.96 cr profit. The numbers are audited.

What’s new

Kabra Drugs recorded ₹92.74 cr in revenue for FY26 after reporting nil revenue in FY25.
Net profit swung to ₹4.96 cr from a prior-year loss of ₹1.08 cr.
Auditors gave the results a clean, unmodified opinion with no capital-use deviations.

Why it matters

For a company with a market capitalisation of just ₹59 cr, generating revenue that is 57% larger than its entire market value in one year is a stark scale change. The clean audit opinion validates the numbers. What's left to prove is whether the new manufacturing strategy can sustain this level.

What we’re watching

Q1 FY27 results to see if the revenue run-rate holds.
Details on which sectors are driving the new manufacturing revenue.
Cash-flow generation from the new operations.

The full read

Kabra Drugs went from nil revenue in FY25 to ₹92.74 crore in FY26. The nano-cap, with a market capitalisation of just ₹59 crore, swung to a net profit of ₹4.96 crore from a loss of ₹1.08 crore. The scale jump is real. It traces back to a single strategic pivot: a new multi-sector manufacturing initiative. The auditors' unmodified opinion matters. It confirms the turnaround is reflected in signed-off books, with no flagged deviations in capital use. The open question is sustainability. One year of execution from a ₹59 cr company proves a strategy can start. It doesn't prove it can last.

Primary source: BSE · NSE